Increased serum fibroblast growth factor 23 predicts mortality in people with HIV/HCV coinfection.
Mohamed ShengirCarine FillebeenJohn WagnerAgnihotram V RamanakumarMohammed KaouacheMarina B KleinKostas PantopoulosGiada SebastianiPublished in: Journal of acquired immune deficiency syndromes (1999) (2023)
In patients with HIV/HCV coinfection, FGF23 may be used as prognostic biomarker for risk stratification accounting also for death causes other than those attributable to liver fibrosis.